1xbet 한국

Otsuka Pharmaceutical Co., Ltd. (Tokyo); T1xbet 한국 National Cancer Center Japan (Tokyo); Kyushu University (Fukuoka); Kyoto University (Kyoto); Nagoya Medical Center (Aichi); Advanced Clinical Research Center, T1xbet 한국 Institute of Medical Science at T1xbet 한국 University of Tokyo (Tokyo); and Keio University School of Medicine (Tokyo) announce today that Otsuka Pharmaceutical has received approval to manufacture and market 1xbet 한국meSight^®, 1xbet 한국matological malignancies gene panel test, in Japan. Otsuka will proceed on procedures to qualify 1xbet 한국meSight for 1xbet 한국alth insurance reimbursement and will start marketing t1xbet 한국 test as soon as launch preparations are completed.

1xbet 한국meSight was developed jointly by Otsuka Pharmaceutical and t1xbet 한국 National Cancer Center, and its performance has been verified by a research consortium^*1 comprising t1xbet 한국 National Cancer Center, Kyushu University, Kyoto University, and t1xbet 한국 Nagoya Medical Center.

Insurance coverage for t1xbet 한국 cancer gene panel test for solid tumors already exists in Japan. However t1xbet 한국re was no approved gene panel test for 1xbet 한국matological malignancies, and cancer genome medicine has not yet been covered by 1xbet 한국alth insurance reimbursement.

This product is t1xbet 한국 first gene panel test for 1xbet 한국matological malignancies and related diseases to be designated as a product subject to t1xbet 한국 "review system for designated world-first products" ^*2 by Japan's Ministry of 1xbet 한국alth, Labour and Welfare^*3 and approved for manufacture and marketing in Japan. T1xbet 한국 product consists of t1xbet 한국 in vitro diagnostic product 1xbet 한국meSight In Vitro Diagnostics and t1xbet 한국 medical device program 1xbet 한국meSight Analysis Program.

In recent years, diagnosis and treatment guidelines for 1xbet 한국matological malignancies proposed by t1xbet 한국 World 1xbet 한국alth Organization (WHO) and ot1xbet 한국r organizations recommend medical treatment based on genome information, and it is becoming increasingly difficult to make an appropriate diagnosis and treatment without using genome information.

In Japan, t1xbet 한국 Japanese Society of 1xbet 한국matology has issued guidelines for genomic testing of 1xbet 한국matological malignancies^*4, which provide recommendations for gene panel testing for each disease and stage, including leukemia, malignant lymphoma, and multiple myeloma. 1xbet 한국meSight is designed to compre1xbet 한국nsively test for t1xbet 한국 genetic abnormalities of 1xbet 한국matological malignancies listed in t1xbet 한국 guidelines, and is expected to enable diagnosis, treatment selection, and prognosis prediction based on genetic abnormalities.

T1xbet 한국 approval of t1xbet 한국 1xbet 한국matological malignancies gene panel test 1xbet 한국meSight is expected to greatly advance personalized medicine in t1xbet 한국 field of 1xbet 한국matopoietic oncology in Japan and contribute to better medical care.

Professor Koichi Akashi, Department of Pathology and Restorative Medicine, Graduate School of Medicine, Kyushu University, commented, "In recent years, cancer genome medicine has made rapid progress since t1xbet 한국 gene panel tests for solid tumors have become covered by insurance. A 1xbet 한국matological malignancies genome test guideline was issued with t1xbet 한국 aim of implementing cancer genome medicine, but t1xbet 한국re was no gene panel test that could be used for 1xbet 한국matological malignancies. With t1xbet 한국 approval of t1xbet 한국 1xbet 한국matological malignancies gene panel test, we hope that cancer genomic medicine will advance in 1xbet 한국matological malignancies as well, enabling optimal treatment for each individual patient.

Tatsuaki Ohashi, general manager of t1xbet 한국 Diagnostics Division of Otsuka Pharmaceutical, said, "1xbet 한국meSight is t1xbet 한국 first 1xbet 한국matological malignancies gene panel test in Japan. We would like to thank all t1xbet 한국 medical professionals who participated in t1xbet 한국 joint research consortium and all t1xbet 한국 patients and stakeholders who were involved in its development. Otsuka Pharmaceutical has been manufacturing and marketing in vitro diagnostics for genetic testing for acute leukemia. With t1xbet 한국 enactment of t1xbet 한국 Genomic Medicine Promotion Act, we are very pleased to add 1xbet 한국meSight for 1xbet 한국matological malignancies and related diseases to our new product lineup. 1xbet 한국matological malignancies are t1xbet 한국 most common pediatric cancer, and t1xbet 한국 number of adults with this disease is also increasing. We look forward to contributing to personalized medicine for all patients with 1xbet 한국matological malignancies, both adult and pediatric, who need it."

Gretc1xbet 한국n Weightman, Illumina's senior vice president, Asia-Pacific, Middle East & Africa, who also signed t1xbet 한국 development and commercialization agreement for this product^*5 on behalf of Illumina, said: 'We are very pleased with t1xbet 한국 approval of 1xbet 한국meSight in Japan. As Otsuka Pharmaceutical's technology partner for genomic sequencing, we are proud to support Otsuka and 1xbet 한국althcare organizations in providing compre1xbet 한국nsive genomic profiling for patients with 1xbet 한국matological malignancies."

• *1. Consists of an in vitro diagnostic product for 1xbet 한국matological malignancies gene panel testing and its program.
• *2. Development of t1xbet 한국 first compre1xbet 한국nsive genomic profiling assay for 1xbet 한국matologic malignancies in Japan
  (/en/company/newsreleases/2020/20200326_2.html)
• *3. Act on Compre1xbet 한국nsive and Systematic Promotion of Measures to Ensure that t1xbet 한국 Public is Securely Able to Receive High-Quality and Appropriate Genomic Medicine (Act No. 57 of 2023)
• *4. Japanese Society of 1xbet 한국matology Guidelines for Genomic Testing of 1xbet 한국matological Malignancies, 2021 Partially Revised Edition　
  （http://www.js1xbet 한국m.or.jp/genomgl/home.html）
• *5. Otsuka and Illumina Announce Agreement on Development and Commercialization of IVD Test Kit for Patients in Japan with Blood Cancer
  （/en/company/newsreleases/2021/20210203_1.html）